350 related articles for article (PubMed ID: 23346859)
21. [Advances in molecular biology of extended-spectrum beta-lactamase].
Xiang Q; You XF; Jiang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Apr; 28(2):298-303. PubMed ID: 16733924
[TBL] [Abstract][Full Text] [Related]
22. Redefining extended-spectrum beta-lactamases: balancing science and clinical need.
Giske CG; Sundsfjord AS; Kahlmeter G; Woodford N; Nordmann P; Paterson DL; Cantón R; Walsh TR
J Antimicrob Chemother; 2009 Jan; 63(1):1-4. PubMed ID: 18957393
[TBL] [Abstract][Full Text] [Related]
23. New beta-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting.
Rossolini GM; Docquier JD
Future Microbiol; 2006 Oct; 1(3):295-308. PubMed ID: 17661642
[TBL] [Abstract][Full Text] [Related]
24. Carbapenem-hydrolysing beta-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil.
Peirano G; Seki LM; Val Passos VL; Pinto MC; Guerra LR; Asensi MD
J Antimicrob Chemother; 2009 Feb; 63(2):265-8. PubMed ID: 19028717
[TBL] [Abstract][Full Text] [Related]
25. Extended-spectrum beta-lactamases in North America, 1987-2006.
Bush K
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():134-43. PubMed ID: 18154537
[TBL] [Abstract][Full Text] [Related]
26. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.
Moland ES; Hanson ND; Black JA; Hossain A; Song W; Thomson KS
J Clin Microbiol; 2006 Sep; 44(9):3318-24. PubMed ID: 16954267
[TBL] [Abstract][Full Text] [Related]
28. β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview.
Gutkind GO; Di Conza J; Power P; Radice M
Curr Pharm Des; 2013; 19(2):164-208. PubMed ID: 22894615
[TBL] [Abstract][Full Text] [Related]
29. Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-β-lactamases.
Santucci M; Spyrakis F; Cross S; Quotadamo A; Farina D; Tondi D; De Luca F; Docquier JD; Prieto AI; Ibacache C; Blázquez J; Venturelli A; Cruciani G; Costi MP
Sci Rep; 2017 Dec; 7(1):17716. PubMed ID: 29255163
[TBL] [Abstract][Full Text] [Related]
30. Class D β-lactamases: a reappraisal after five decades.
Leonard DA; Bonomo RA; Powers RA
Acc Chem Res; 2013 Nov; 46(11):2407-15. PubMed ID: 23902256
[TBL] [Abstract][Full Text] [Related]
31. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
Livermore DM; Mushtaq S; Nguyen T; Warner M
Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
[TBL] [Abstract][Full Text] [Related]
33. Structural and Mechanistic Basis for Extended-Spectrum Drug-Resistance Mutations in Altering the Specificity of TEM, CTX-M, and KPC β-lactamases.
Palzkill T
Front Mol Biosci; 2018; 5():16. PubMed ID: 29527530
[TBL] [Abstract][Full Text] [Related]
34. Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases.
Tsivkovski R; Totrov M; Lomovskaya O
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32152086
[TBL] [Abstract][Full Text] [Related]
35. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
[TBL] [Abstract][Full Text] [Related]
36. Fluorescein-labeled beta-lactamase mutant for high-throughput screening of bacterial beta-lactamases against beta-lactam antibiotics.
Chan PH; Chan KC; Liu HB; Chung WH; Leung YC; Wong KY
Anal Chem; 2005 Aug; 77(16):5268-76. PubMed ID: 16097768
[TBL] [Abstract][Full Text] [Related]
37. beta-Lactam resistance and beta-lactamases in bacteria of animal origin.
Li XZ; Mehrotra M; Ghimire S; Adewoye L
Vet Microbiol; 2007 Apr; 121(3-4):197-214. PubMed ID: 17306475
[TBL] [Abstract][Full Text] [Related]
38. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability.
Chen Y; Delmas J; Sirot J; Shoichet B; Bonnet R
J Mol Biol; 2005 Apr; 348(2):349-62. PubMed ID: 15811373
[TBL] [Abstract][Full Text] [Related]
39. Extended-spectrum beta-lactamases: an actual problem of hospital microbiology (a review).
Szabó D; Barcs I; Rozgonyi F
Acta Microbiol Immunol Hung; 1997; 44(4):309-25. PubMed ID: 9554165
[TBL] [Abstract][Full Text] [Related]
40. [Gram-negative bacteriae with resistance to carbapenems].
Nordmann P
Med Sci (Paris); 2010 Nov; 26(11):950-9. PubMed ID: 21106177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
